Neurofibrillary tangles composed of exon 10+ microtubule associated protein tau (MAPT) deposits are the characteristic feature of the neurodegenerative diseases progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). PSP, CBD, and more recently Alzheimer's disease and Parkinson's disease, are associated with the MAPT H1 haplotype, but the relationship between genotype and disease remains unclear. Here we investigate the hypothesis that H1 expresses more exon 10+ MAPT mRNA compared to the other haplotype, H2, leading to a greater susceptibility to neurodegeneration in H1 carriers.
Introduction
The human microtubule associated protein tau (MAPT; or tau) locus lies on chromosome 17q21 and the protein is important in establishing and maintaining neuronal morphology.
Six tau isoforms are expressed in the adult human central nervous system, produced by alternative splicing of exons 2, 3 and 10. Alternative splicing of exon 10 leads to a protein containing either three (3R; exon 10-) or four (4R; exon 10+) tandem repeats of a microtubule-binding motif (1) . Accumulation of hyperphosphorylated intracellular tau aggregates known as neurofibrillary tangles (NFTs) is seen in Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), frontotemporal dementia (FTD) and Pick's Disease (PiD), neurodegenerative disorders collectively referred to as tauopathies (2) . In PSP and CBD the NFTs contain an excess of 4R tau protein, hence these diseases are known as 4R-tauopathies, although there is no significant increase in soluble 4R tau protein. It has also been shown that in PSP and CBD patients there is an increase in exon 10+ (4R) MAPT mRNA transcripts in regions of the brain most severely affected by neurodegeneration (3, 4) . In AD the NFTs are composed of equal amounts of 4R and 3R tau, and in PiD the tau is mainly of the 3R form. Alterations in the ratio of wild-type 4R to 3R MAPT transcripts have been found in families with inherited frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) (5, 6) in which splice-site mutations clustered in the intronic sequences immediately following exon 10 generate transcripts constitutively including exon 10 from the mutant allele (5, 6, 7) . More recently, a shift in 4R:3R ratios in favour of 4R MAPT mRNA transcripts has been found in mild cognitive impairment and AD (8, 9), suggesting that disruption in 4R:3R ratios may underlie a broad range of neurodegeneration disease.
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Two haplotypes exist at the MAPT locus, H1 and H2, of which H1 is significantly over-represented most notably in PSP and CBD (10-12). More recently, H1 variants have been found associated with AD (13) and Parkinson's disease (PD) (14) . Linkage disequilibrium (LD) across the region is very high and the two haplotype blocks are correspondingly large, most recently estimated as between 1-2 Mb in size (15, 16) . The cause of the high LD has been recently shown to be the presence of a 900 kb chromosomal inversion containing the MAPT locus, in which the H2 MAPT locus is inverted relative to H1 (ref. 17) . Interestingly, the inversion on the H2 chromosome has been shown to be under positive selection in Europeans (17) .
It is clear, therefore, that haplotype-specific sequence variation exists at critical points across the MAPT locus. We are interested in the hypothesis that polymorphisms within the MAPT H1 haplotype sequence are responsible for subtle, higher levels of exon 10+ (4R) MAPT transcript expression from H1 chromosomes, leading, over time, to a greater susceptibility to neurodegenerative disease. Allele-specific, or haplotype-specific, gene expression represents a powerful tool to quantify the effect of sequence variation on transcript expression (18, 19) . Analysis of allele-specific gene expression within a heterozygous sample provides internal control against confounding environmental variables which would otherwise exist between samples. Here we apply the methodology to investigate haplotype-specific differences both in total MAPT transcript expression, and specifically in exon 10+ (4R) MAPT expression. Importantly, any effect of underlying genetic polymorphic variation on gene expression and splicing is independent of disease status and can be performed either in human neuronal cell lines, or in control post-mortem brain samples, of a known genotype.
Here we analyse MAPT expression in heterozygous human model neuronal cultures, and in post-mortem brain tissue, where the level of transcript expression between the H1 and H2 chromosomes can be directly compared in the same sample. We find that the H1 haplotype expresses significantly more exon 10+ (4R) MAPT transcript than H2. The deviation in expression from the expected 1:1 ratio is greatest in the globus pallidus, a region consistently affected by tau pathology, where the maximum observed exon 10+ (4R)
MAPT H1:H2 transcript ratio is 1.425, (SD=0.205; p<0.0001). These data suggest a mechanism for the increased susceptibility of H1 carriers to neurodegeneration and may explain why the H2 haplotype, which has been shown to confer a protective effect against 4R tauopathy, is under positive selection in Caucasian populations.
Results

Allele-specific expression assay design
Polymorphisms present in coding sequences can be used as a tag to distinguish between allelic transcripts and are required in order to undertake allele-specific expression assays in a heterozygous sample, such as a cell line or in brain tissue. We used three previously-defined (10) coding single nucleotide polymorphisms (SNPs) in the MAPT gene as the basis for our haplotype-specific expression assays. SNP 1 (rs17650901) lies in exon 1 and was used to compare total MAPT transcript expression between haplotypes. Two SNPs in exon 9, SNP 9i (rs1052553) and SNP 9ii (rs17652121), were used to specifically assay haplotypeexpression of exon 10+ (4R) MAPT mRNA. All three of the SNPs have been previously shown to be in complete linkage disequilibrium with the 238 bp insertion/deletion polymorphism in intron 9 (ref. 10) used in this study to define the H1 and H2 haplotypes (Fig. 1A) .
by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from Page 6 The allele-specific gene expression methodology utilises a reverse-transcription (RT)-PCR reaction, followed by a primer extension reaction using either a forward or reverse extension primer, and then analysis of the base extension products by matrix-assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-ToF MS; see Materials and Methods). The ratio of H1 to H2 MAPT transcripts can be measured in either the total MAPT mRNA pool, or specifically in the exon 10+ (4R) MAPT mRNA pool, depending on the initial RT-PCR primers selected. Details of all the DNA oligonucleotides used in the study are shown in Fig. 1 and Table 1 . The methodology has significant advantages over quantitative reverse transcriptase PCR (Q-RT-PCR) because Q-RT-PCR requires that certain assumptions must be made regarding the expression of control genes used to normalise the measurements.
Cell culture models
We first screened a panel of 14 genetically-independent human neuronal and three commonly-used non-neuronal cell lines for the presence (H1) or absence (H2) of a 238 bp insertion/deletion polymorphism in intron 9 previously used to define the H1 and the H2 haplotypes. Two neuronal lines, SK-N-F1 and SK-N-MC, were found to be H1/H2 heterozygotes, with the remainder being H1/H1 homozygotes ( Table 2) .
MAPT H1/H2 heterozygous cell lines SK-N-F1 and SK-N-MC were differentiated to induce a neuronal-like phenotype using a two-stage neuronal differentiation protocol originally optimised for use with SH-SY-5Y neuroblastoma cells (20) . Briefly, cells plated at low density were first grown in medium supplemented with 10 µM retinoic acid. After five days the retinoic acid supplement was removed and the cells were grown in Neurobasal medium containing 2 mM dibutyryl cyclic AMP plus 50 ng/ml brain derived neurotrophic factor (BDNF) for a further five days (see Materials and Methods). During this differentiation phase cells stop dividing and extend long, neuronal-like processes.
Immunocytochemistry staining showed the differentiated cells now expressed neuronal marker proteins such as neurofilament protein heavy chain (NF-H), microtubule associated protein 2 (MAP2) and tau ( Fig. 2A) . To investigate the suitability of the cell cultures to model a pure neuronal population, we then analysed differentiated SK-N-F1 and SK-N-MC cells for the expression of glial fibrillary acidic protein (GFAP), a marker of glial cells ( (Fig. 3) . Performing the initial RT-PCR reaction using a reverse primer in exon 10 specifically sampled from the exon 10+ (4R) MAPT transcript pool and revealed a significantly greater expression from the H1 chromosome using both SNP 9i and SNP 9ii in both cell lines (p<0.0001 in all cases by one sample t-test) (Fig. 3) . At SNP 9i and SNP 9ii it was possible to analyse the transcript ratios present by performing the base extension reaction on the RT-PCR product using both the forward and reverse primers. Both the forward and reverse primers independently show higher expression of exon 10+ (4R) MAPT transcript from H1 for both exon 9 SNPs in both cell lines (data not shown).
Together, these data show that in two independent neuronal cell culture models of MAPT endogenous gene expression the neurodegeneration-associated MAPT H1 haplotype expresses a significantly greater amount of exon 10+ (4R) MAPT mRNA.
MAPT expression in post-mortem brain tissue
We then extended our study to human post-mortem brain samples. Forty control cases with no evident pathological signs of neurodegenerative disease (see Supplementary Table 1 for details) from the Brain Bank held by the Oxford Project to Investigate Memory and Ageing (OPTIMA) were genotyped using the H1/H2 insertion-deletion polymorphism in intron 9.
Fourteen of the forty control brains (35%) were identified as being from H1/H2 heterozygotes, from which we obtained frontal cortex (BA46) and globus pallidus frozen tissue. The globus pallidus and frontal cortex were chosen for gene expression analysis as regions severely affected by NFTs in the 4R-tauopathies PSP and CBD, respectively. cDNA prepared from both brain regions of the fourteen controls was used as a template for PCR amplification followed by primer extension and MALDI-ToF MS analysis. Allele-specific expression analysis of total MAPT transcript using SNP 1 is shown in Fig 4A. We then compared haplotype-specific expression of the neurodegenerationassociated exon 10+ (4R) MAPT mRNA transcript using SNP 9i and SNP 9ii ( 
-test).
In summary, the data show first, that the strength of the MAPT genomic DNA promoter does not vary significantly between the H1 and H2 chromosomes in human brain tissue as assayed at SNP 1, and second, that the H1 chromosome expresses a significantly greater amount of exon 10+ (4R) MAPT mRNA than H2, with the greatest deviation of up to 1.43-fold found in the globus pallidus and 1.29-fold in the frontal cortex. Our data suggest it is this relative over-expression of exon 10+ (4R) MAPT mRNA from H1 which may contribute to the susceptibility to tauopathy. We analysed expression of exon 10+ (4R)
MAPT transcripts using forward and reverse primer base extension reactions at SNP 9i and 9ii to measure allelic differences. Importantly, the independent forward and reverse primer data at both SNPs in both brain regions were consistent in showing significant overexpression of exon10+ (4R) MAPT transcript from H1 compared to H2 (data not shown).
Recent work has uncovered sequence variation within the H1 haplotype and identified H1 sub-haplotypes associated with PSP (15, 21, 22), AD (13) and PD (14) . We genotyped the H1/H2 brain tissue for SNPs rs1467967, rs242557/htSNP167, rs3785883, rs2471738 and rs7521 to determine the H1 sub-haplotype present (21, 22). We first subdivided the brain samples into two groups ("A" allele: n=7; "G" allele: n=7) based on the SNP rs242557/htSNP167 in intron 0, proposed as a SNP within a transcription binding site responsible for modulating total MAPT transcript expression (22). There was no significant difference between the H1:H2 transcript ratios between the "A" and "G" allele samples in globus pallidus (p=0.533) or frontal cortex (p=0.069) by Student's t-test. In a second analysis we subdivided the fourteen heterozygote samples based on the presence or absence of the proposed Class II haplotype (21), which includes the two alleles conferring greatest risk to PSP, rs242557 and rs2471738. In this analysis (Class II: n=4; non-Class II: n=10) there was no significant difference between the levels of total MAPT H1:H2 transcript ratios between the Class II and non-Class II haplotype samples in the globus pallidus (p=0.554) or frontal cortex (p=0.269) by Student's t-test.
MAPT splice ratios in different brain regions
These data suggest that allele-specific differences of MAPT exon 10 expression in the brain, particularly in the globus pallidus, contribute to the susceptibility to suffering from 4R-tauopathies. We used the MALDI-ToF MS platform to further investigate the ratio of exon 10+ (4R) to exon 10-(3R) MAPT transcript levels in the globus pallidus and frontal cortex using the assay shown in Fig. 1B and C. We found that in thirteen of the fourteen (93%) control brains, the ratio of MAPT 4R:3R transcripts was significantly higher in the globus pallidus than the frontal cortex (p<0.0001 in each individual brain by one sample t-test), with the ratio ranging from 1.3 to 3.5 (mean=1.652, SD=0.6180) (Fig. 5) . This higher 4R:3R
MAPT transcript ratio in the globus pallidus compared to the frontal cortex in control brain tissue provides a further link between MAPT gene expression and the greater susceptibility of the globus pallidus to accumulating 4R-tau NFTs compared to the frontal cortex.
Discussion
Functionally-important sequence variation in the human genome lying outside coding regions is likely to be critically important in the understanding of human disease. As we rapidly accumulate DNA sequence data for the human genome, it is becoming increasingly important to utilise methodologies to help us uncover the effect of polymorphic variation on gene expression. Allele-specific, or haplotype-specific, gene expression represents a powerful tool to quantify the effect of genomic variation on gene expression.
Traditionally, candidate gene analysis has focused on coding variants. However, several recent studies examining susceptibility to neurological disorders have found strong association with disease of specific alleles or haplotypes lacking obvious changes in proteincoding sequences. In such cases detailed investigation has focused on variation in gene expression regulated by non-coding polymorphisms. A study investigating the genetic basis of dyslexia found association to a 77 kb region on chromosome 6p22 (23). One risk haplotype was identified within this region which contained no coding variants. Further investigation revealed an approximate 40% relative reduction in expression of the KIAA0319 gene from this risk haplotype (24). Allele-specific expression analysis has also been applied at two loci that have been identified as candidates conferring susceptibility to schizophrenia: catechol-O-methyltransferase (COMT) (25) and dystrobrevin binding protein 1 (DTNBP1) (26). At the COMT locus on chromosome 22q11 mRNA transcripts bearing an allele associated with schizophrenia showed an average 17% relative reduction in expression (25).
At the DTNBP1 locus on chromosome 6p22 the schizophrenia-associated risk haplotype showed 21% less expression of DTNBP1 compared to chromosomes bearing either one of two non-risk haplotypes (26). A study on promoter polymorphisms in the GABA A receptor beta3 subunit (GABRB3) gene used in vitro luciferase reporter assays to demonstrate a 40% reduction of GABRB3 from a promoter haplotype associated with childhood absence epilepsy (CAE) (27). Finally, a study of expression of APOE in human brain tissue revealed a 15-25% increase in expression of the ε4 allele of the APOE gene, the strongest risk factor for late onset Alzheimer's Disease (28). In each case discussed above the subtle changes in relative gene expression between risk and non-risk alleles have been suggested as a functional mechanism whereby a risk haplotype confers susceptibility to disease.
The genetic association of the MAPT sequence variation with PSP and CBD is wellestablished and has been widely-replicated since the first studies (11, 29). The associations with PD (14, (30) (31) (32) (33) and AD (13) are more recent, but do, however, support recent suggestions that genetic variation in expression and splicing at the MAPT locus may be critical to a wide range of neurodegenerative disorders (34) . Finally, recent findings suggesting aberrations in 4R:3R ratios in mild-cognitive impairment and AD (8, 9) support the involvement of MAPT from the earliest stages of disease.
There are two potential mechanisms by which haplotype-specific expression at the MAPT locus may confer susceptibility to tauopathy: there may be allelic variation in total MAPT expression, or in expression of a disease-susceptibility variant. Our study has used allele-specific gene expression assays in H1/H2 heterozygous neuronal cell cultures and The significant advantage of our work compared to reporter gene studies using short fragments of DNA is that we are comparing expression of H1 and H2 transcripts from the actual MAPT genomic DNA locus in its correct chromosomal location in an internally controlled experiment. By analysing gene expression from the complete and intact MAPT locus we have been able for the first time to study the effect of MAPT haplotype on the ratio of expression of 4R:3R transcript. We propose it is the haplotype-specific difference in exon 10+ (4R) MAPT expression, rather than a haplotype-specific difference in MAPT promoter activity, which underlies the mechanism by which H1 contributes to disease susceptibility.
Finally, the experimental design of a within-sample analysis between two loci of a heterozygous sample eliminates confounding environmental factors which would create a high level of noise in a between-sample analysis of post-mortem brain tissue, such as comorbidity, age at death, cause of death and sample quality.
We find strong evidence for allelic differences in expression of exon 10+ (4R) MAPT mRNA between the H1 and H2 chromosomes. It is also possible that there may be more subtle differences in expression between different sub-haplotypes of H1, but that our sample size is too small to be further subdivided to detect small differences. Importantly, the SNPs by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from defining the H1 sub-haplotypes do not include a coding SNP, which means it is not possible to perform a direct comparison using the method of analysis we describe.
We observed the most dramatic relative over-expression of exon 10+ (4R) MAPT mRNA from H1 in the globus pallidus, a region of the basal ganglia severely affected by NFTs in PSP, and also to a lesser extent in CBD. We showed that in thirteen of the fourteen brains with no overt neuropathology the 4R:3R MAPT transcript ratio was higher in the globus pallidus than frontal cortex. This provides a further link at the molecular level with pathology and may explain why the globus pallidus is more susceptible to suffering a buildup of NFTs than the frontal cortex. As with other complex disease loci it remains an enormous challenge to attempt to define which of the polymorphic variants is responsible for differences in gene expression observed between haplotypes in MAPT. Work in our laboratory is now focused on using novel bacterial artificial chromosomes (BAC)-based genomic DNA expression systems to dissect the functional importance of sequence variation at the MAPT locus (35, 36) .
Materials and Methods
Cell culture: The following neuronal cell lines were purchased from the European Fig. 1 and the complete sequences are given in Table 1 .
Quantitation of haplotype-specific gene expression: DNA fragments amplified by PCR were treated by exonuclease I (New England BioLabs) to remove residual primers, followed by incubation with shrimp alkaline phosphatase (Amersham Biosciences) to dephosphorylate unincorporated deoxynucleotides. The fragments were then used as templates for a primer extension reaction using a mixture of three dideoxynucleotides and one deoxynucleotide in the reaction. The primer extension reaction products were then analysed by matrix-assisted laser desorption/ionisation-time of flight mass spectrometry by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from (MALDI-ToF MS) using the MassARRAY system on Sequenom platform. Each MALDI-ToF MS assay was repeated eight times, comprising four independent RT-PCR reactions, each analysed in duplicate. Three well-characterised haplotype-specific SNPs in complete linkage disequilibrium with the 238 bp insertion/deletion polymorphism in intron 9 (ref. 10) used to define H1 and H2, were used to identify chromosome-specific transcripts and then quantify their relative amounts (see Fig. 1 ). For SNP 1 (rs17650901)
each assay was performed eight times using the reverse extension primer. For SNP 9i
(rs1052553) and SNP 9ii (rs17652121) each assay was performed eight times using both the forward and reverse extension primers as independent assays and a mean of the sixteen readings was taken, with three exceptions for SNP 9i in which only the reverse extension primer was used. The MassARRAY data were processed by the Sequenom SpectroTYPER software to obtain the area under the primer extension product trace curves. Genomic DNA was used to produce a standardised ratio equivalent to equal expression from each chromosome. In the case of assays to measure ratios of 4R:3R splice variants, artificial constructs were prepared containing fragments of exons 9, 10 and 11. Each construct contains a single copy of exon junctions and was therefore used as the normalising control (see Fig. 1 ). Statistical analysis was performed as previously described (24) using a one sample t-test which calculates a p-value indicating the significance of the observed allelic differences in expression from the expected ratio of 1. Oligonucleotide identification letters refer to the sequences given in Table 1 
